Ligand, a biopharmaceutical company located in San Diego, agreed to acquire APEIRON Biologics, a biotechnology company in Vienna, Austria, for $128m. "The addition of QARZIBA to our commercial royalty portfolio further supports our growth strategy to invest in high-value medicines that deliver significant clinical value and generate predictable and long-term revenue streams for our investors. QARZIBA is the only immunotherapy for high-risk neuroblastoma marketed across Europe and in other parts of the world. We believe this drug will be a meaningful contributor to our royalty revenue, which is now driven by a diversified portfolio of 12 key commercial-stage products," Todd Davis, Ligand CEO.